Influence and safety of tirofiban on platelet inhibition rate in patients with acute ST-segment elevation myocardial infarction
Duan Xiaochun
Zeng Yujie
Liu Meiyan
Abstract：To review the influence and safety of tirofiban on platelet inhibition rate in patients with acute ST-segment elevation myocardial infarction (STEMI). Methods Acute STEMI patients (n=82) were chosen from the Center for Emergency and Critical Medicine of Beijing Anzhen Hospital affiliated to Capital University of Medical Sciences from Mar. 2013 to Feb. 2014, and randomly divided into tirofiban group (n=42) and control group (n40). The tirofiban group was given tirofiban 30 min before PCI, and then tirofiban in micro-dose was continuously pumped for 36 h. And coronary angiography (CAG) was conducted routinely and PCI was only used for intervene infarction-related vessels in tirofiban group. The control group was given heparin before PCI. The platelet inhibition rate and platelet activity were detected before and after medicinal interventions. The major adverse cardiovascular events (MACE) and bleeding situation were recorded in 2 groups within 30 d after PCI. Results The platelet inhibition rate increased [(59.8 ±17.3)% vs. (80.3±8.6)%] and activity decreased [(58.2±7.3) mm vs. (46.9±11.5) mm] in tirofiban group compared with control group after tirofiban treatment for 24 h (P<0.05). The incidence of MACE was lower in tirofiban group than that in control group (9.5% vs. 20.0%, P<0.05), and incidence of bleeding had no statistical significance between 2 groups (P>0.05). Conclusion Tirofiban can significantly raise platelet inhibition rate and reduce platelet activity without bleeding risk in acute STEM patients, and it is safe and effective.
Keywords：TirofibanPlatelet inhibition rateThrombelastogramMyocardial infarction
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 739-741 )